Status:
COMPLETED
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hyp...
Eligibility Criteria
Inclusion
- Patients with essential hypertension
Exclusion
- Severe hypertension
- History or evidence of a secondary form of hypertension
- History of myocardial infarction.
- Other protocol-defined inclusion exclusion criteria also apply.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
976 Patients enrolled
Trial Details
Trial ID
NCT00294710
Start Date
March 1 2005
End Date
July 1 2006
Last Update
November 8 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
East Hanover, New Jersey, United States, 07936
2
Investigative Centers, Germany